The U.S. FDA authorizes Hemerion’s IND application for its Pentalafen® / Heliance® product combination

The FDA authorization enables Hemerion to commence a Phase 1/2 clinical study at University of Pittsburgh Medical Center by Q4 2023 to evaluate the upgraded Pentalafen® / Heliance® platform.

Read the press release